

**Form 51-102F3**  
**Material Change Report**

**Item 1 Name and Address of Company**

Kaneh Bosm BioTechnology Inc. (the "Issuer")  
Suite 810– 789 West Pender Street  
Vancouver, BC V6E 3T5

**Item 2 Date of Material Change**

June 13, 2018

**Item 3 News Release**

The news release was disseminated on June 13, 2018 by way of the facilities of Stockwatch and Market News Publishing Inc. Copies were also filed on SEDAR with the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission

**Item 4 Summary of Material Change**

The Company announced that Mr. Peter Nguyen has been appointed as the Issuer's Chief Financial Officer. The appointment follows the resignations of Mr. Anthony Jackson as the Issuer's Chief Financial Officer.

**Item 5 Full Description of Material Change**

**5.1 Full Description of Material Change**

Please see the attached news release dated June 13, 2018.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

Not applicable.

**Item 8 Executive Officer**

The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted:

Eugene Beukman, Director

Business Telephone: 604-687-2038

**Item 9 Date of Report**

June 13, 2018

**Kaneh Bosm BioTechnology Inc.**  
**810 – 789 West Pender Street**  
**Vancouver BC V6C 1H2**  
**Tel: 604.687.2308**

**NOT FOR DISSEMINATION IN THE UNITED STATES**

---

**NEWS RELEASE**

---

**June 13, 2018 – Vancouver, B.C. - - Kaneh Bosm BioTechnology Inc. (the “Company”) (CSE: KBB)  
Appoints Peter Nguyen as its Chief Financial Officer**

Kaneh Bosm BioTechnolgy Inc. (KBB:CSE) (“Kaneh Bosm” or the “Company”) is pleased to announce the appointment of Mr. Peter Nguyen as its Chief Financial Officer (“CFO”).

Peter Nguyen is a Chartered Accountant and holds a degree from the University of British Columbia. He has held senior financial positions for both public and private companies where he provided assurance, corporate finance, tax and business advisory services.

The appointment follows the resignation of Mr. Anthony Jackson as the Company’s CFO. Kaneh Bosm would like to thank Anthony for his many years of service to the Company and wishes him well with his future endeavors.

On behalf of the Board of Directors of Kaneh Bosm Biotechnology Inc.

“Eugene Beukman”

Eugene Beukman

Director

[EBeukman@pendergroup.ca](mailto:EBeukman@pendergroup.ca)

604-687-2038

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking

statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on [www.sedar.com](http://www.sedar.com)